Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-mesothelin TNhYP218 CAR T cells

A preparation of autologous T lymphocytes containing primarily naive and stem cell-like memory (scm) T cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the membrane-proximal region of the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-MSLN TNhYP218 CAR T cells specifically target the membrane-proximal region of MSLN and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Targeting the membrane-proximal region of MSLN may increase the killing of tumor cells and improve T-cell persistence. Naive and scm T cells may exhibit increased persistence and decreased exhaustion.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-mesothelin TNaive/SCM hYP218 CAR T cells
autologous anti-MSLN hYP218 CAR naive and stem cell-like memory T cells
autologous anti-MSLN TNhYP218 CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search